Thr1530
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Thr1530 - ITGB4 (human)

Site Information
LTAGVPDtPTRLVFS    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: ITGB4 iso2 (human): T1460, ITGB4 (rat): T1514, ITGB4 iso2 (mouse): T1461, ITGB4 iso3 (human): T1513, ITGB4 (mouse): T1526, ITGB4 iso3 (mouse): T1514
Blast this site against: NCBI  SwissProt  PDB 

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (1, 2, 3, 4, 5, 6, 7, 8, 9)
Disease tissue studied: gastric cancer (1, 2, 3, 4), gastric carcinoma (1, 2, 3, 4)
Relevant cell line - cell type - tissue: HeLa (cervical) (7), HeLa S3 (cervical) (6), HT-29 (intestinal) (8, 9), MKN-45 (gastric) (1, 2, 3, 4), MV4-11 (myeloid) (5)




References

1

(2011) CST Curation Set: 11301; Year: 2011; Biosample: MKN-45; Disease: gastric carcinoma; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

2

(2011) CST Curation Set: 11325; Year: 2011; Biosample: MKN-45; Disease: gastric carcinoma; Treatment: normal; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

3

(2011) CST Curation Set: 11327; Year: 2011; Biosample: MKN-45; Disease: gastric carcinoma; Treatment: normal; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

4

(2011) CST Curation Set: 11330; Year: 2011; Biosample: MKN-45; Disease: gastric carcinoma; Treatment: normal; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

5

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

6

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

7

Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92
16964243   Curated Info

8

(2005) CST Curation Set: 658; Year: 2005; Biosample: HT-29; Disease: colorectal carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXtP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

9

(2005) CST Curation Set: 800; Year: 2005; Biosample: HT-29; Disease: colorectal carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXtP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.